MicroRNA player MiRagen bags $40M round and a public stock listing in reverse merger
Boulder, CO-based MiRagen Therapeutics has found its way into the public markets, reverse merging with struggling Signal Genetics and gaining a $40 million round to finance its next stage of development.
The microRNA biotech had completed another $40 million crossover round last fall, just as the market was shriveling for high-risk biotech plays. Its new syndicate includes Fidelity Management and Research Company, Brace Pharma Capital, Atlas Venture, Boulder Ventures, JAFCO Co., Ltd., MP Healthcare Venture Management, MRL Ventures (Merck), Remeditex Ventures, and others.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.